Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRX103 in HSCT for GvHD Prevention
NCT06462365Phase 1Recruiting
- Sponsor
- Tr1X
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Regulatory T Cells (Tregs), Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TRX103 in graft-versus-host disease (GVHD), sponsored by Tr1X. Primary endpoints: Incidence of Adverse Events up to 1 year, Stem Cell Engraftment and Donor Chimerism and 1 more. Started Apr 2024; status: recruiting.
02
Drugs
TRX103
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06462365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06462365.